Arrive AI Earnings Call Transcripts
Fiscal Year 2025
-
Revenue remains modest as the company prioritizes infrastructure and product refinement, with most Q4 revenue from a single healthcare deployment. Leadership expansion, robust patent growth, and a strengthened balance sheet position the business for future scale.
-
Q3 saw recurring revenue growth, a narrowed net loss, and aggressive hiring, supported by a $4M capital draw and a $10M share buyback. Expansion in healthcare and international partnerships, plus regulatory tailwinds, position the company for scalable autonomous logistics growth.
-
Q2 marked a transition from R&D to commercial execution, with first-ever revenue, major partnerships, and a public listing. Despite a net loss driven by one-time listing costs, cash flow was positive and a $40M capital facility remains largely untapped. The five-year plan targets rapid scaling and a 10x increase in enterprise value.